4.6 Article

Neuropsychiatric Symptoms as Predictors of Progression to Severe Alzheimer's Dementia and Death: The Cache County Dementia Progression Study

期刊

AMERICAN JOURNAL OF PSYCHIATRY
卷 172, 期 5, 页码 460-465

出版社

AMER PSYCHIATRIC PUBLISHING, INC
DOI: 10.1176/appi.ajp.2014.14040480

关键词

-

资金

  1. Cache County Memory Study
  2. Dementia Progression Study
  3. Joseph and Kathleen Bryan Alzheimer's Disease Research Center (National Institute on Aging) [R01AG11380, R01AG21136, R01AG18712]
  4. Associated Jewish Federation of Baltimore
  5. AstraZeneca
  6. Bristol-Myers Squibb
  7. Eisai
  8. Elan
  9. Forest
  10. Functional Neuromodulation
  11. GlaxoSmithKline
  12. Lilly
  13. National Football League
  14. NIA
  15. NIMH
  16. Novartis
  17. Ortho-McNeil
  18. Pfizer
  19. Weinberg Foundation

向作者/读者索取更多资源

Objective: Little is known about factors influencing the rate of progression of Alzheimer's dementia. Using data from the Cache County Dementia Progression Study, the authors examined the link between clinically significant neuropsychiatric symptoms in mild Alzheimer's dementia and progression to severe dementia or death: Method: The Cache County Dementia Progression Study is a longitudinal study of dementia progression in incident cases of this condition. Survival analyses included unadjusted Kaplan-Meier plots and multivariate Cox proportional hazard models. Hazard ratio estimates controlled for age at dementia onset dementia duration at baseline, gender, education level,. General Medical Health Rating, and apotipoprotein E epsilon 4 genotype. Results: Three hundred thirty-five patients with incident Alzheimer's dementia were studied. Sixty-eight (20%) developed severe dementia over the follow-up period. Psychosis (hazard ratio=2.007), agitation/aggression (hazard ratio=2.946), and any one clinically significant neuropsychiatric symptom (domain score >= 4 hazard ratio=2.682) were associated With more rapid progression to severe dementia. Psychosis (hazard ratio=1.537), affective symptoms (hazard ratio=1.510), agitation/aggression (hazard ratio=1.942), mildly symptomatic neuropsychiatric symptoms (domain score of 1-3, hazard ratio=1448), and clinically significant neuropsychiatric symptoms (hazard ratio=1.951) were associated with earlier death. Conclusions: Specific neuropsychiatric symptoms are associated with shorter survival time from mild Alzheimer's dementia to severe dementia and/or death. The treatment of specific neuropsychiatric symptoms in mild Alzheimer's dementia should be examined for its potential to delay time to severe dementia or death.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据